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Heart failure is a clinical syndrome that is predominantly caused by cardiovascular disorders
such as coronary heart disease and hypertension. However, several classes of drugs may induce
heart failure in patients without concurrent cardiovascular disease or may precipitate the
occurrence of heart failure in patients with preexisting left ventricular impairment. We
reviewed the literature on drug-induced heart failure, using the MEDLINE database and
lateral references. Successively, we discuss the potential role in the occurrence of heart failure
of cytostatics, immunomodulating drugs, antidepressants, calcium channel blocking agents,
nonsteroidal anti-inflammatory drugs, antiarrhythmics, beta-adrenoceptor blocking agents,
anesthetics and some miscellaneous agents. Drug-induced heart failure may play a role in only
a minority of the patients presenting with heart failure. Nevertheless, drug-induced heart
failure should be regarded as a potentially preventable cause of heart failure, although
sometimes other priorities do not offer therapeutic alternatives (e.g., anthracycline-induced
cardiomyopathy). The awareness of clinicians of potential adverse effects on cardiac
performance by several classes of drugs, particularly in patients with preexisting ventricular
dysfunction, may contribute to timely diagnosis and prevention of drug-induced heart failure.
(J Am Coll Cardiol 1999;33:1152–62) © 1999 by the American College of Cardiology
Congestive heart failure (CHF) is a complex clinical syn-
drome that results from cardiac dysfunction (1). Signs and
symptoms that are frequently encountered in patients suf-
fering from CHF are dyspnea, fatigue, pulmonary crepita-
tions and peripheral edema. Its clinical course is often
characterized by periods of exacerbating symptoms, alter-
nated with periods in which the patient experiences fewer or
no symptoms. Epidemiologic studies indicate that both the
prevalence and the incidence of CHF increase (2–4).
Congestive heart failure is predominantly caused by
cardiovascular diseases, such as coronary artery disease,
hypertension and valvular heart disease (3,5). However, in
some patients the occurrence of CHF can be attributed to
the cardiotoxic effect of a particular drug. Furthermore, as
several categories of drugs may exert unfavorable hemody-
namic effects, these drugs may act as a precipitating factor
for a relapse in patients with previously compensated CHF.
Pathophysiologically, CHF may result from drug-mediated
effects on cardiac preload, cardiac afterload or myocardial
contractility. Drugs that increase cardiac preload or cardiac
afterload may have unfavorable effects on ventricular func-
tion, because increased cardiac preload or afterload intensi-
fies the demand on ventricular performance. The ability of
the heart to comply with this increased demand will depend
on preexisting ventricular function. Drugs may also have a
negative inotropic effect as a result of their direct cardiotoxic
properties. Similarly, the likelihood of the occurrence of
heart failure induced by cardiotoxic drugs may depend on
preexisting ventricular function, although some drugs may
have detrimental effects in patients with previously normal
cardiac function. We will discuss the potential ability of
several categories of drugs to induce or exacerbate heart
failure.
CYTOSTATICS
Anthracyclines. The anthracyclines are effective antineo-
plastic agents which are used in the treatment of many types
of malignancy. Daunorubicin and doxorubicin are among
the most frequently used anthracyclines included in chemo-
therapeutic regimens (6). The anthracyclines are antibiotic
agents which antineoplastic action results from the inhibi-
tion of the nucleic acid synthesis by binding to both strands
of the deoxyribonucleic acid (DNA) helix. This binding
prevents normal function of the ribonucleic acid (RNA) and
DNA polymerases. The introduction of the anthracyclines
has contributed considerably to the improvement of survival
in patients with cancer. However, anthracycline-induced
cardiotoxicity is a well-known adverse effect of this category
of drugs and a major limitation to the total dose that can
safely be administered (6). Cardiotoxicity is considered to be
an adverse effect of all anthracyclines, although epirubicine
may cause less cardiotoxicity as compared with doxorubicine
(7). Formation of free oxygen radicals, disturbance of the
mitochondrial energy metabolism and intracellular calcium
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overloading are considered mechanisms in the pathogenesis
of anthracycline-induced cardiotoxicity (8). Based on the
dose-dependency of the anthracycline-induced impairment
of left ventricular function, an upper limit of the cumulative
dose of 550 mg/m2 is generally recommended. When this
upper limit of the cumulative dose is exceeded, early heart
failure may develop in about 30% of the patients receiving
these high dosages (6). Anthracyclines as part of a combined
chemotherapeutic regimen, however, may induce heart fail-
ure at a cumulative dosage below 550 mg/m2 (9). In
particular, combined chemotherapeutic treatment with cy-
clophosphamide seems to be associated with an increased
risk of cardiotoxicity, even when the cumulative dose of the
anthracycline remains below 400 mg/m2. The addition of
cytoprotective agents to chemotherapeutic schemes, such as
the bispiperazinedione compound ICRF187, seems to re-
duce cardiotoxicity significantly without reducing antineo-
plastic action (10,11).
Cardiotoxicity may develop at any moment during or after
treatment with anthracyclines. Although anthracycline-
induced cardiotoxicity is usually characterized by heart failure,
cardiac arrhythmias might be the first manifestation in some
patients.
Early cardiac toxicity, which occurs during or soon after
treatment with anthracyclines, is mainly dependent on the
cumulative anthracycline dose (6). However, the develop-
ment of heart failure several years after the last administra-
tion of anthracyclines is increasingly recognized. In a study
among 201 children who had completed chemotherapy with
anthracyclines, decreased fractional shortening on echocar-
diography was present in more than 60% of the patients
who had received .500 mg/m2 and were followed up for at
least 10 years (12). Although an adequate control group was
lacking, these findings indicate that anthracycline-induced
heart failure may develop several years after completing
treatment with anthracyclines. Interestingly, in those pa-
tients of whom an end-therapy echocardiogram was avail-
able, it could be demonstrated that decreased fractional
shortening at the end of the therapy was strongly associated
with decreased fractional shortening at long-term follow-
up. Although numbers were small, more than 70% (10/14)
of the patients with decreased fractional shortening at the
end of the therapy still had decreased systolic function at
long-term follow-up. In contrast, of patients with a normal
echocardiogram at the end of therapy, only 12% (8/64) had
decreased fractional shortening at long-term follow-up
(p , 0.001). Patients suffering from anthracycline-induced
cardiotoxicity may finally develop signs and symptoms
of heart failure when impaired systolic function is unable
to maintain hemodynamic homeostasis. Although
anthracycline-induced heart failure is generally consid-
ered to be irreversible, some reports on complete recovery
of cardiac dysfunction have been published (13).
The severity of anthracycline-induced cardiomyopathy
can be quantified with the help of a morphologic grading
system (14). In an endomyocardial biopsy, anthracycline
toxicity is characterized by sarcotubular dilation and myo-
fibrillar loss of actin and myosin. Long-term myocardial
damage has also been identified in patients who had
received doses of only 45 mg/m2 (15). Therefore, all
patients exposed to anthracyclines should be considered
at risk for the development of heart failure as a result of
the cardiotoxic properties of these agents. To evaluate
cardiotoxicity, guidelines for monitoring cardiac function
have been implemented in most anthracycline-containing
chemotherapeutic regimens (16). The treatment of
anthracycline-induced heart failure does not differ from
the general pharmacotherapeutic approach to heart fail-
ure patients. Diuretics, angiotensin-converting enzyme
inhibitors and digoxin are the mainstays of treatment. In
some patients with severe anthracycline-induced CHF,
heart transplantation may finally remain the only thera-
peutic option.
Cyclophosphamide. Cyclophosphamide is an alkylating
agent that causes cytotoxicity by its biologically active
metabolites. Reports have been published on both com-
pletely reversible cases as well as on fatal cases of CHF
attributed to cyclophosphamide-induced cardiomyopathy
(17,18). Cardiotoxicity of cyclophosphamide is thought to
be due to toxic endothelial damage followed by extravasa-
tion of toxic metabolites with resultant myocyte damage and
interstitial hemorrhage and edema (19). Symptoms of CHF
usually appear within two weeks after administration of the
drug. In patients who develop severe progressive CHF, this
complication may lead to death within a few weeks. Based
on analyses of the plasma concentration time curves (area
under the curve, AUC) in 19 women with metastatic breast
cancer, treated with a continuous 96-h infusion of cyclo-
phosphamide, it has been shown that a low AUC and a low
peak plasma level of cyclophosphamide were predictive for
both an increased duration of response as well as for an
increased risk of developing CHF. These findings suggest
that patients with a more extensive metabolism of cyclophos-
phamide are more prone to develop cyclophosphamide-
induced cardiotoxicity. In this way, measurement of the AUC
may draw attention to those patients who are most susceptible
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to develop heart failure. The numerous reports on both
reversible and irreversible heart failure indicate a wide spectrum
of cyclophosphamide-induced cardiotoxicity, which can be
influenced by preexisting cardiovascular condition, other che-
motherapeutic regimens received before treatment with cyclo-
phosphamide and the dose and method of administration of
cyclophosphamide (20).
Paclitaxel. Paclitaxel belongs to an important new class of
anticancer agents, the taxanes. Paclitaxel promotes the
polymerization of tubulin. Microtubules formed in the
presence of paclitaxel are extraordinarily stable and dysfunc-
tional. These dysfunctional microtubules interfere with
normal cell division and interphase processes and may
eventually lead to cellular death. Paclitaxel is increasingly
used in the treatment of patients with advanced ovarian and
breast cancer. Transient asymptomatic bradycardia appears
to be the most frequent cardiovascular adverse effect, re-
ported in up to 29% of the patients treated with paclitaxel
(21). Clinically important cardiac bradyarrhythmias appear
to have an incidence of only 0.1%. In a case report, the onset
of heart failure has been associated with the administration
of paclitaxel (22). Furthermore, heart failure has been
reported with a remarkable frequency in an uncontrolled
study of Gianni et al. in which women with metastatic
breast cancer who had never received chemotherapy were
treated with the combination of paclitaxel by 3-h infusion
and doxorubicin (23). Six out of 33 patients (18%) devel-
oped symptomatic heart failure within 12 months after
starting this treatment. The median received dose of doxo-
rubicin in these patients was 480 mg/m2. Based on previous
studies, an incidence of symptomatic heart failure in the
range of 1% to 10% should be expected within one year after
treatment with doxorubicin at the commonly used total dose
limit of 550 mg/m2. Therefore, an incidence of 18% has
raised the question whether the combined treatment of
paclitaxel and doxorubicin may account for this apparently
increased risk of heart failure. Other studies, however, in
which different schedules of the combined administration of
paclitaxel and doxorubicin were used did not indicate an
increased risk of heart failure (23). This finding may suggest
that the schedule used for the administration of paclitaxel
and doxorubicin may influence the risk of CHF. On the
other hand, as all patients who developed CHF in the study
of Gianni et al. had cardiovascular risk factors or a history of
radiotherapy of the cardiac region, baseline differences
among the patients included in these studies may also
account for differences in the risk of paclitaxel-induced
CHF. In summary, unequivocal evidence of paclitaxel-
induced CHF is lacking. However, due to the efficacy of
paclitaxel as an antineoplastic agent, paclitaxel will un-
doubtedly be prescribed to an expanding group of patients
outside the setting of clinical trials in the near future. As the
risk of cardiotoxicity in patients with concomitant cardio-
vascular disease is unknown, there is a need for additional
information on the risk of CHF after administration of
paclitaxel in patients with concomitant cardiovascular co-
morbidity.
Mitoxantrone. Mitoxantrone is structurally related to
doxorubicin and has also been associated with the develop-
ment of left ventricular impairment. In a study in 801
patients treated with mitoxantrone, a clinical diagnosis of
CHF was made in 1.5% of the patients, whereas in another
1.5% of the patients reduced left ventricular ejection fraction
developed without clinically overt CHF (24). Furthermore,
cumulative mitoxantrone dose was associated with an in-
creasing risk of cardiotoxicity. Conclusions should be drawn
cautiously, as a control group was not included in this study.
Decreased left ventricular ejection fraction has also been
observed in a study in which patients were treated with
mitoxantrone and where patients with preexisting cardiac
disease or previous exposure to anthracyclines were excluded
(25). The findings from these studies and the structural
relationship with doxorubicin support the hypothesis that
mitoxantrone should be regarded as a potentially cardiotoxic
agent that may be associated with drug-induced CHF.
Other chemotherapeutic agents. Heart failure has been
associated with several other chemotherapeutic agents such
as 5-fluorouracil (5-FU) and cytarabin. Cardiac toxicity
induced by 5-FU is usually characterized by chest pain and
signs of ischemia, which resemble angina pectoris and is
generally accepted to be caused by 5-FU–induced coronary
spasms (26). There have also been reports in which the
occurrence of severe but reversible left ventricular dysfunc-
tion was attributed to use of 5-FU (27–29), although the
extent to which 5-FU may have accounted for the occur-
rence of CHF is not always obvious. As a result of
5-FU–induced coronary spasm, decreased ventricular func-
tion may also be caused by myocardial ischemia instead of
by a direct toxic effect on the myocardium (30). In a
retrospective study on cardiotoxic effects of 5-FU and folinic
acid in 390 patients treated for gastrointestinal cancer, heart
failure occurred in only one patient (31). Therefore, the
association between heart failure and 5-FU should be
evaluated in future studies. Cytarabine-induced reversible
CHF seems to be very rare and has only been described in
a case report (32).
Recently, Herceptin (recombinant humanized anti-
HER2 antibody) has been approved for the treatment of
breast cancer in the U.S. Herceptin inhibits the growth of
cancer cells overexpressing HER2. The HER2 gene en-
codes a transmembrane tyrosine–kinase receptor, desig-
nated p185HER2. Antibodies directed at p185HER2 have
been shown to inhibit growth of tumors that express high
levels of this receptor (33). As overexpression of HER2
appears to be present in a considerable number of patients
suffering from breast, ovarian and gastric cancer, Herceptin
may be of value in the treatment of several different cancers.
A recent study has shown that patients whose tumor cells
have increased levels of p185HER2 do significantly better
when Herceptin is added to standard chemotherapy. How-
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ever, concern has been raised on cardiac toxicity, which
occurred in a number of patients participating in a trial on
breast cancer treatment. About 27% of the patients using
doxorubicin, paclitaxel and Herceptin experienced signs of
cardiac dysfunction, compared with 6% of those using only
doxorubicin and paclitaxel (34). Although Herceptin may
be considered as a potential improvement in the treatment
of cancer, its cardiac toxicity might restrict its applicability
in clinical practice. Therefore, cardiac toxicity should be a
major point of concern in ongoing and future trials.
ANTIARRHYTHMICS
The cardiodepressant adverse effects of antiarrhythmic
drugs can mainly be attributed to their negative inotropic
properties. Particularly, in patients with preexistent left
ventricular impairment, antiarrhythmics can induce or ex-
acerbate CHF. Proarrhythmic effects that may occur during
treatment with antiarrhythmics may further contribute to
the induction or worsening of CHF. The degree of negative
inotropy may vary from drug to drug. Class III antiarrhyth-
mics, however, are usually considered as lacking these
negative inotropic properties. Pathophysiologically, the neg-
ative inotropic effects of antiarrhythmic drugs are mediated
by alterations of the intracellular calcium content (35). The
ultimate effect on myocardial contractility of antiarrhyth-
mics does not only depend on their true negative inotropic
effect, but also on additional effects on the peripheral
circulation, preexisting myocardial function and their effect
on the prevailing arrhythmia.
Patients with decreased left ventricular function are at
increased risk of both ventricular and supraventricular ar-
rhythmias. Sudden death, attributed to the occurrence of an
acute ventricular arrhythmia, is frequently encountered in
patients with CHF. Not only are patients with impaired left
ventricular function more prone to develop cardiac arrhyth-
mias, but the cardiac arrhythmia itself may have a deleteri-
ous effect on left ventricular performance. Therefore, despite
their potential negative inotropic effects and proarrhythmo-
genic effects, antiarrhythmic drugs are frequently needed in
patients with CHF (36).
Randomized double-blinded placebo-controlled trials
have indicated an increased risk of CHF for those patients
assigned to treatment with an antiarrhythmic drug (37,38).
Although most antiarrhythmic drugs have intrinsic negative
inotropic effects and have been associated with the occur-
rence of CHF (39–45), there seem to be differences among
the various antiarrhythmic agents (39–45). In a randomized
crossover study in 21 patients with severe left ventricular
impairment (mean left ventricular ejection fraction 21%),
tocainide and encainide were significantly more likely to
cause hemodynamic and clinical deterioration as compared
with procainamide (46). Conclusions should be cautiously
drawn, however, as the results may have been influenced by
dose and route of administration of the antiarrhythmic drug
and the evaluation of only the short-term effect of a single
dose. Despite some differences among the various antiar-
rhythmic agents, nearly all antiarrhythmic drugs should be
considered as potentially disadvantageous with respect to
left ventricular contractility.
BETA-ADRENOCEPTOR ANTAGONISTS
Congestive heart failure is a well-known adverse effect of
beta-adrenoceptor antagonists (beta-blockers). The negative
chronotropic and negative inotropic properties of these
drugs can easily induce or exacerbate CHF in patients with
a propensity to this condition. Interestingly, also the topical
administration of beta-blockers in patients with glaucoma
has been associated with the occurrence of CHF in some
case reports (47–49). Convincing evidence of systemic
effects after topical administration of beta-blockers has been
provided (50–54). In a pharmaco-epidemiologic study using
automated databases, however, no relation between the use
of topical beta-blockers and the occurrence of CHF could
be revealed (55). Apart from methodologic limitations, this
finding only indicates that on a population level, the topical
administration of beta-blockers does not appear to be
associated with a significantly increased risk of hospitaliza-
tion for CHF. In susceptible individuals, however, the
systemic effects of topical beta-blockers may suffice to
induce or exacerbate CHF.
Interestingly, a new approach to the management of
CHF includes the use of beta-adrenergic antagonists. As
activation of the sympathetic nervous system is considered
to be an important pathophysiologic mechanism in the
progression of CHF, interference with the activated sym-
pathetic nervous system appears to have beneficial effects in
animal models of CHF (56,57). Although long-term trials
on the effects of metoprolol and bisoprolol did not provide
convincing evidence with respect to reduction of morbidity
and mortality in patients with CHF (58,59), a recent trial
with carvedilol demonstrated a reduced risk of death and
hospitalization for cardiovascular causes (60). Carvedilol is
one of the new beta-adrenergic agents with alpha-1–
blocking and antioxidant properties. As a result of these
additional properties of carvedilol, it remains unclear
whether its favorable effects should be attributed to its
beta-adrenergic antagonistic effect or to the additional
properties of this agent. Ongoing additional studies on the
effects of beta-adrenergic antagonists should demonstrate to
what extent these drugs can contribute to the current
treatment of patients with CHF. To prevent acute beta-
adrenergic antagonistic effects in patients with CHF, start-
ing dosages should be low and can be gradually increased if
tolerated.
NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
Nonsteroidal anti-inflammatory drugs (NSAIDs) have been
associated with fluid retention and the onset of CHF in
several publications (61–66). Congestive heart failure which
is induced or exacerbated by NSAIDs is not mediated by a
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direct myocardial depressant effect of NSAIDs. The major
mechanism of action of NSAIDs is the interference with
prostaglandin (PG) biosynthesis by inhibiting the function
of the enzyme cyclooxygenase (COX) (67). Furthermore,
NSAIDs also interfere with the effects of diuretics and
angiotensin-converting enzyme inhibitors (68 –70). In
healthy individuals, PGs play a negligible role in maintain-
ing renal blood flow and consequently, NSAIDs usually
exert no significant effects on renal hemodynamics (71,72).
In patients with an impaired left ventricular function,
however, PGs play an important role in the maintenance of
cardiovascular and renal homeostasis. Prostaglandins have a
vasodilatory effect on the afferent arteriole, oppose the
effects of angiotensin II on the systemic circulation and
decrease total body sodium and water. These effects of PGs
are considered to contribute significantly to the mainte-
nance of compensated heart failure in patients with im-
paired left ventricular function. In these patients, NSAIDs
may interfere with cardiovascular homeostasis and may
induce or exacerbate CHF (73).
Two isoforms of COX have been identified, COX-1 and
COX-2. Cyclooxygenase-2 is predominantly involved in all
stages of the inflammatory response, whereas COX-1 is
mainly responsible for the synthesis of prostaglandin E2
(PGE2) and PGI2 in kidney and stomach (67). To prevent
the potentially adverse effects on renal function, so-called
renal-sparing NSAIDs have been introduced, such as sulin-
dac, nabumetone and meloxicam. These agents have been
reported to exert less adverse effects on renal function
(74–78). However, comprehensive data on the effects of
these agents on renal function and cardiovascular homeosta-
sis in patients with decreased left ventricular function are
not yet available.
CALCIUM CHANNEL BLOCKING AGENTS
For many years, there has been concern about the extent to
which calcium channel blocking drugs may contribute to the
exacerbation of CHF in patients with preexisting left
ventricular dysfunction. As calcium channel blocking drugs
are widely prescribed for the treatment of angina pectoris in
patients with preexisting left ventricular impairment, this
concern should be regarded as fully legitimated. Most
calcium channel blockers currently approved for clinical use
belong to three distinct chemical classes: the phenylalky-
lamines (e.g., verapamil), the dihydropyridines (e.g., nifed-
ipine) and the benzothiazepines (e.g., diltiazem). In the
SOLVD trial, calcium antagonists were found to be used in
30% of patients with CHF (79). Several pathophysiologic
mechanisms that contribute to the potential effects of
calcium channel blocking on left ventricular function have
been described (80). These mechanisms can be character-
ized by a negative inotropic effect on the heart, caused by
impeding the transmembrane cellular calcium transport, and
the activation of endogenous neurohormonal systems such
as the renin–angiotensin system and the sympathetic ner-
vous system. Marked hemodynamic and clinical deteriora-
tion can occur in patients with CHF when the negative
inotropic effects of calcium channel blockers are not coun-
terbalanced by their vasodilatory effects (81,82). It has been
postulated that the ability to improve the vascular compli-
ance of the arterial tree may be a crucial determinant with
respect to the effect of a particular calcium channel blocker
on the natural course of CHF (83). This may also be an
explanation for the observed effects of calcium channel
blockers on the occurrence of CHF in some trials. In the
Multicenter Diltiazem Postinfarction Trial (MDPIT),
postinfarction patients with a baseline ejection fraction of
less than 0.40 who were treated with diltiazem had a
statistically significantly increased risk of subsequent CHF
(84). The risk of CHF rose progressively with increasing
impairment of left ventricular ejection fraction at baseline.
Life table analysis excluded the possibility that the observed
effect could be attributed to improved survival of those
patients who were treated with diltiazem. However, some
caution with respect to these findings is warranted, as the
hypothesis was formulated after completion of the study.
Furthermore, the diagnosis of CHF was not required to
satisfy specific predefined criteria. Although the double-
blind design of the study prevents any differential misclas-
sification, a complex clinical syndrome such as CHF should
preferably comply with well defined diagnostic criteria.
Although calcium channel blockers intrinsically depress
myocardial contractility, increased left ventricular ejection
fraction can be observed after the administration of dihy-
dropyridines such as nefidipine. This can be explained by
the reflex stimulation of the sympathetic nervous system
which counterbalances the intrinsic negative inotropic effect
of the dihydropyridines (85). However, it has been shown
that chronic administration of nefidipine in patients with
CHF may have deleterious effects (86). Recently, results
from the PRAISE-trial (Prospective Randomized Amlo-
dipine Survival Evaluation Trial) indicated that amlodipine
5 to 10 mg/day in patients with CHF had no significant
effect on cardiovascular events and mortality (87). Subgroup
analyses in this trial pointed out that the benefit of amlo-
dipine was only seen in patients with nonischemic cardio-
myopathy. In a similar trial (V-HeFT III), felodipine
showed neither beneficial nor unfavorable effects as com-
pared with placebo (88). Although the vasodilatory effects of
calcium channel blockers should be regarded as beneficial
for patients with CHF, the negative inotropic effect and
activation of neurohormonal systems by calcium channel
blockers have unfavorable effects in these patients. Amlo-
dipine, one of the newer dihydropyridines, may be of benefit
in patients with nonischemic cardiomyopathy.
ANESTHETICS
During general anesthesia, cardiovascular homeostasis will
be subject to several influences. Patient characteristics, such
as age and concomitant comorbidity, intravenous fluid
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administration, surgical procedures and medication used
during general anesthesia may all affect cardiovascular ho-
meostasis. Therefore, the occurrence or exacerbation of
signs and symptoms of CHF in close relationship with
general anesthesia cannot always easily be attributed to a
specific agent used during general anesthesia. Nevertheless,
a number of agents that are used during general anesthesia
may have negative effects on myocardial contractility. The
halogenated volatile anesthetics halothane and enflurane
both have mild negative inotropic effects (89). In particular,
halothane has been associated with cardiodepressant effects
(90). Negative inotropic effects, however, have been found
to be more pronounced in patients with preexisting left
ventricular impairment (91). Cardiodepressant effects seem
to be less frequent when using newer agents such as
isoflurane and desflurane, although it has been suggested
that these differences may apply only to young patients (92).
The intravenous barbiturate anesthetics thiopental and
methohexital may also depress myocardial contractility. In
general, the hemodynamic consequences of usual plasma
levels of these agents are limited (93). In patients who are
more susceptible to the potential cardiodepressant effect of
these agents, such as the elderly and patients with impaired
left ventricular function, cautious dosages and proper fluid
administration may prevent undesirable hemodynamic ef-
fects.
Propofol is an intravenous induction anesthetic that is
also used for sedation in intensive care units. Most fre-
quently reported adverse effects are bradycardia and hypo-
tension. The hypotensive effect of propofol is considered to
be brought about by peripheral vasodilation, inhibition of
the sympathetic nervous system and reduced myocardial
contractility (94). Long-term sedation with propofol in
children has been associated with fatal myocardial failure,
whereas the use in adults appears to be safe with respect to
this effect (95). It has been suggested that the relatively high
dosages might be responsible for the deleterious effects in
children.
IMMUNOMODULATING DRUGS
Interferons. Three types of interferons, interferon-alpha,
interferon-beta and interferon-gamma, are used for clinical
indications. Interferon-alpha and -beta exert antiviral and
antiproliferative activities, whereas interferon gamma acts
primarily as an immunoregulatory cytokine. Interferon-
alpha has been associated with cardiovascular adverse effects,
such as hypotension and tachycardia during the first days of
treatment in 5% to 15% of the patients (96). Cardiac adverse
effects of the interferons are cardiac arrhythmias, cardiomy-
opathy and symptoms of ischemic heart disease (97). There
have been case reports on both reversible and irreversible
severe CHF after treatment with interferon-alpha (98–
100). A clear pathophysiologic understanding of interferon-
alpha–induced cardiomyopathy is lacking. Both impairment
of myocyte metabolism as well as increased oxygen demand
as a result of fever and tachycardia may be involved in the
onset of CHF (98,100). Until now, interferon-beta has not
been associated with the onset of CHF (97). Cardiovascular
effects attributed to treatment with interferon-gamma, such
as hypotension and arrhythmia, have been observed in
patients treated with high dose interferon-gamma. In most
instances, these patients had a history of preexistent cardio-
vascular disease. Although cardiovascular adverse effects
seem to be infrequent, CHF has been reported as a possible
adverse effect of interferon-gamma (102).
Interleukin-2. Interleukin-2 (IL-2), which has been ap-
proved for the treatment of metastatic renal cell carcinoma,
may have serious cardiovascular adverse effects. Hypoten-
sion and tachycardia are almost invariably encountered in
patients treated with IL-2. Reversible left ventricular dys-
function has also been demonstrated in patients treated with
IL-2, using echocardiography or radionuclide ventriculog-
raphy (103,104). It has been suggested that the production
of cytokines may have a central role in the development of
IL-2–induced cardiac dysfunction. Cytokines may inhibit
the accumulation of cellular cyclic adenosine monophos-
phate, which may blunt myocardial contractility. Histologic
findings of eosinophilic and mixed lymphocytic–
eosinophilic myocarditis attributed to IL-2 indicate a pos-
sible drug hypersensitivity syndrome (105).
ANTIDEPRESSANT DRUGS
Antidepressant drugs are usually divided into three main
categories: classical antidepressants (mainly consisting of the
tricyclic compounds), second generation antidepressants
(including the selective serotonin reuptake inhibitors
[SSRI]) and monoamine oxidase inhibitors. The cardiovas-
cular effects of the tricyclic antidepressants (TCAs) have
always been a source of concern, in particular when the
prescription of a TCA is indicated in patients with cardio-
vascular comorbidity. Sinus tachycardia occurs in the ma-
jority of patients treated with TCAs, and approximately
20% of the patients may experience postural hypotension
(106). Tricyclic antidepressant–induced postural hypoten-
sion is attributed to the combined effect of its peripheral
antiadrenergic action, its myocardial depressant effect and
its alpha-adrenergic blocking effect in the central nervous
system. Compared with other TCAs, nortriptyline is only
rarely associated with the occurrence of orthostatic hypo-
tension (107). Tricyclic antidepressants also affect atrioven-
tricular conduction by prolongation of the conduction time
in the His bundle and the bundle branches, prolonging the
duration of QRS interval and corrected QT interval (108).
Second- and third-degree atrioventricular block may occur
and lead to asystole and sudden death. Tricyclic antidepres-
sants are highly concentrated in myocardial tissue, which
partly explains their interference with heart rate, cardiac
rhythm and myocardial contractility. The effects of TCAs
on myocardial function are mediated by several mecha-
nisms, such as their anticholinergic and quinidine-like
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action, interference with the reuptake of adrenergic amines,
alterations of membrane permeability and direct myocardial
depression (42). Several studies have been performed on the
effects of TCAs on left ventricular function. There have
been case reports of CHF attributed to the use of TCAs
(109,110). Experiments in animals indicate that TCAs may
have a negative inotropic effect (111), particularly in higher
doses, although the findings from these experimental animal
studies are difficult to extrapolate to human subjects. Results
from noninvasive studies in which systolic time interval
measurements are used as a parameter of left ventricular
function suggest that TCAs impair cardiac function
(112,113). However, the systolic time interval depends on
cardiac conduction, which may have been influenced by
TCAs. Therefore, these indirect measurements of left
ventricular function do not provide convincing evidence of a
direct TCA-induced cardiodepressant effect at the level of
myocardial cells. More recent studies in which left ventric-
ular contractility was assessed by radionuclide ventriculog-
raphy failed to demonstrate TCA-induced left ventricular
impairment. In 20 nondepressed patients with moderate to
severe baseline ventricular impairment who were treated
with imipramine (mean daily dose 210 mg) or nortriptyline
(mean daily dose 100 mg) for ventricular premature depo-
larizations, no significant changes in mean ejection fraction
could be observed (114). Studies of Veith et al. and
Glassman et al. in patients with decreased baseline ejection
fraction also indicate that TCAs have no significant effects
on left ventricular ejection fraction (115,116). These studies,
however, are characterized by a small sample size, selection
of patients and a short period of follow-up. Despite these
limitations, most studies indicate that the effects of TCAs
on left ventricular function seem to have no major conse-
quences for their applicability in everyday clinical practice.
Even in patients with preexistent left ventricular impair-
ment, there is no convincing evidence indicating that TCAs
are likely to have deleterious effects on left ventricular
function. However, as CHF is frequently accompanied by
disturbances of cardiac conduction or low arterial blood
pressure, and long-term information on the effect on ven-
tricular performance of TCAs in heart failure patients is
scarce, clinicians should be aware of possible adverse car-
diovascular effects when prescribing TCA to patients with
severe CHF.
Selective serotonin reuptake inhibitors have a very low
rate of adverse cardiovascular effects. It has been estimated
that the incidence of adverse cardiovascular events is under
0.0003% (117). This estimate, however, is based on re-
ported cases of cardiovascular events to the pharmaceutical
company. Although estimates of the incidence of adverse
reactions that are based on the number of reported cases
should be regarded with caution, the overall impression is
that SSRI have a very low incidence of adverse cardiovas-
cular effects. Probably the most important effect of SSRI in
patients with cardiovascular comorbidity is their potential to
interact with drugs that these patients are taking for cardiac
arrhythmias, CHF or hypertension. The interaction be-
tween SSRI and several drugs is mediated by the inhibition
of cytochrome P450 enzymes by the SSRI. The SSRI-
induced inhibition of cytochrome P450 affects the metabo-
lism of several classes of drugs, such as antiarrhythmics,
beta-blockers, antihistamines and calcium channel blockers.
It has been suggested that this might have been the cause of
some unexpected deaths in patients who had recently begun
fluoxetine therapy (118). As SSRI are a relatively new class
of drugs, no studies have been performed on their effects on
ventricular function in patients with CHF. Currently avail-
able data on the cardiac effects of SSRI suggest that these
agents do not have direct influence on myocardial function,
but that attention should be drawn to their potential
interactions with several classes of drugs (117,119).
MISCELLANEOUS AGENTS
Apart from the categories of drugs discussed in the previous
paragraphs, various other agents have been associated with
the occurrence or worsening of CHF (see Table 1). Al-
though the pathophysiologic mechanism is rather straight
forward with respect to some agents, for example, miner-
alocorticoid effects of steroidal hormones, in other instances
their causal role remains more obscure. In particular, when
a pathophysiologic mechanism appears to be absent, the
possibility of coincidence can hardly be ruled out. Never-
theless, detailed documentation of all clinical features of
patients with suspected drug-induced CHF, even in the
absence of a straightforward pathophysiologic explanation,
may finally contribute to an objective risk–benefit profile of
the agents involved.
CONCLUSIONS
Several categories of drugs may potentially induce or exac-
erbate CHF. Pathophysiologically, drugs that increase pre-
load, afterload or have negative inotropic properties may be
able to cause this adverse reaction. In Table 1, a distinction
has been made between agents that are commonly regarded
as being able to induce CHF in patients with previously
normal ventricular function and agents which may precipi-
tate CHF in patients with previously compensated CHF.
Obviously, agents that may induce CHF can also precipitate
CHF. Agents reported to induce CHF only very rarely are
mentioned in this table as a third category. Particularly
patients with preexisting left ventricular dysfunction who
already have the propensity to develop CHF appear to be at
risk for drug-induced heart failure. Although the cardiotoxic
effects of drugs such as the anthracyclines and cyclophos-
phamide are obvious and well known, this is not always the
case in all the categories of drugs we discussed. Moreover,
drug-induced cardiac rhythm disorders may also induce
signs and symptoms of CHF in susceptible patients. There-
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fore, detailed documentation of the medication involved
together with all clinical features of patients with suspected
drug-induced CHF may contribute substantially to a reli-
able assessment of both the pathophysiologic mechanism
and the likelihood of causality. This may finally serve as an
appropriate risk–benefit profile of the drugs involved.
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